Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions
Depressive Disorder, Major
Interventions
DRUG

Bupropion extended release

300mg once a daily, PO, 8weeks

Trial Locations (6)

425-707

Korea University Ansan Hospital, Ansan

150-713

Bucheon St.Mary's Hospital, Bucheon-si

442-723

The Catholic University of Korea, St.Vincent Hospital, Suwon

480-717

The Catholic University of Korea, Uijeongbu St. Mary'S Hospital, Uijeongbu-si

780-350

dongguk university MEDICAL CENTER, Kyungju

130-702

Kyung Hee University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Chi-Un Pae

OTHER

NCT01477931 - Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features | Biotech Hunter | Biotech Hunter